Sanid. mil. 2020; 76 (1) 3
Sanidad Militar
Revista de Sanidad de las Fuerzas Armadas de España
Sanid. mil. Volumen 76, número 1. ISSN: 1887-8571 Enero-marzo 2020
CONTENTS
EDITORIAL
5 COVID-19: the new disease X
Ortega García, MV.
ORIGINAL ARTICLE
8 High resolution melting analysis for the equine cerebellar abiotrophy mutation typing
Jiménez Heredia, I.; Quiñones Pérez, C.; Ojeda Durán, FJ.; Matínez-Pinna Vallejo, E.; Gaudó Hernández, M.; Vega-Pla, J.L.
SUMMARY: Introduction: the equine cerebellar abiotrophy is an autosomal recessive neurodegenerative disease. It has been
more frequently described in the Arabian horse. The causative mutation produces a progressive degeneration of Purkinje
cells. Objectives: developing a simple technique based on the high-resolution melt analysis (HRM) in order to identify the
carriers of the mutation among a group of ancestors of an affected horse. Material and methods: DNA extraction of 93 blood
samples from a group of related animals. Primers designed to amplify an 89 base pair sequence that contains the mutation.
Amplification of the sequence and melting curves analysis. Results: the genealogical analysis confirms the autosomal recessive
nature of disease. The amplification did not generate nonspecific fragments. The HRM analysis allowed the differentiation of
healthy and affected homozygous genotypes, and also the differentiation of the carrier, heterozygous genotype. Our results
concur with those obtained using the fragment analysis technique published in 2011. Conclusion: high resolution melting
analysis is a simple technique that allows the detection of cerebellar abiotrophy carriers in horses.
KEYWORDS: equine cerebellar abiotrophy, mutation, high resolution melting analisys (HRM), horse.
13 Atherogenic indexes and body composition in cadets of a colombian military training school
García Muñoz, AI.; Melo Buitrago, PJ.; Rodríguez Arcila, MA.; Silva Zambrano, DA.
SUMMARY: Antecedents: The atherogenic indices are biochemical indicators that are usually related to body fat and the
development of cardiometabolic diseases, which represent a serious problem in public health, not only because of the
associated morbidity and mortality, but also due to the health costs involved, a situation that it is´nt alien in the military
population. Aim: To determine if the body mass index in overweight colombian cadets is due to lean or fat mass and if it
is related to atherogenic indices. Materials and methods: Descriptive - observational study, in overweight cadets, assessed in
the center of physical culture research (CICFI) of the Military School of cadets “General José María Córdova”. For the
analysis of the information the statistical package SPSS 24 was used, applying normality tests, descriptive statistics for normal
behavior data and Pearson’s correlation. Results: 90 cadets with an average age of 22.0 ± 3.0 years and a body mass index of
27.3 ± 1.8 kg / m2, 58.0% men and 32.0% women were included. The pre-erogenous index was related to the BMI (r = 0,305 p
= 0,02), the Castelli index was weakly related to the body mass index (r = 0,254 p = 0,05). In no group, the ratio of triglycerides
was related to BMI. Conclusions: The atherogenic indices in overweight cadets are in normal ranges and have weak relations
with the body mass index. Overweight is due to greater lean mass.
KEYWORDS: Adiposity, cardiometabolic risk, military, atherogenic index, total cholesterol.
TECHNICAL NOTES
19 Positive assessment of drugs: October, November and December 2019
Aparicio Hernández, R.; García Luque, A.; Granda Lobato, P.; Correa Pérez, A.
SUMMARY: The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency
made public in October, November and December of 2019, and considered of interest to the healthcare professional, are
reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.
KEYWORDS: Brolucizumab (Beovu®); Delafloxacino (Quofenix®); Esketamina (Spravato®); Fostamatinib (Tavlesse®)
Glucagón (Baqsini®); Imipenem/Cilastatina/Relebactam
(Recarbrio®); Osilodrostat (Isturisa®); Polatuzumab vedotin
(Polivy®); Romosozumab (Evenity®); Siponimod (Mayzent®); Solriamfetol (Sunosi®);Upadacitinib (Rinvoq®); Vacuna para
ébola virus zaire (Ervebo®).
REPORTS
25 External health supports required during Enhanced Forward Presence III mission (Latvia)
Perez García, A.
SUMMARY: Antecedent and objectives: In July 2016, the eFP (Enhanced Forward Presence) operation was given a green light,
with the aim of providing defense to the Baltic countries members of NATO, against Russia. Spain deployed a contingent in
Latvia, whose health consisted of a stabilization cell and a liaison nurse. In case of needing health support, it was agreed to use
the Canadian ROLE 1 or the latvian civil health services. The objective of this study was to analyze the external health support
required during the Enhanced Forward Presence III mission. Material and Methods: A cross-sectional study was carried
out. The 78 cases of the eFP-III mission were used in which external support had to be managed. Statistical analysis was